HMGCR Inhibition Impairs Mitochondrial Fatty Acid Oxidation in Clinical and Preclinical Models: Therapeutic Targeting of Long-Chain Acylcarnitines

For millions of people, the daily routine of taking a pill to lower cholesterol is a straightforward act of prevention. These medications, known as statins, work by blocking a specific enzyme in the liver that helps the body produce cholesterol. By turning down this production line, the drugs successfully reduce the amount of fat circulating in the blood, lowering the risk of heart attacks and strokes. However, for a significant number of patients, this same treatment brings an unwanted side effect: aching, weak, or tired muscles. Doctors and scientists have long debated the cause of these symptoms. One theory suggests the problem is simply that the body is being starved of a vital chemical it needs to function, while another proposes that the drug directly damages the tiny power plants inside our cells. Resolving this question is crucial, because if the cause is a direct cellular injury, the solution might lie in protecting those power plants rather than just adjusting the dosage of the drug.

A new study has taken a closer look at this biological puzzle, moving beyond the debate to examine what actually happens inside the cells when this enzyme is blocked. The researchers focused on a process called fatty acid oxidation, which is how cells burn fat for energy. They suspected that when the enzyme is inhibited, the cell's ability to burn fat breaks down, causing a toxic buildup of unfinished fuel. To test this, the team looked at two very different groups: patients taking statin medication and mice genetically engineered to lack the enzyme entirely. In the human volunteers, the researchers collected samples of blood and muscle tissue. They found that while the blood looked normal, the muscle tissue told a different story. Inside the muscle cells of those taking statins, the machinery for burning fat was running slower, and there was a noticeable accumulation of medium and long-chain acylcarnitines. These are molecules that act as transporters for fat, but when they pile up because they cannot be processed, they become a sign that the cell's energy system is clogged.

The same pattern appeared in the mice that were genetically designed to lack the enzyme. These animals developed severe health issues, including dangerous drops in blood sugar and damage to the liver, which were linked to a massive buildup of the same fat-carrying molecules. The researchers then asked a critical question: if the problem is this toxic pileup of fat carriers, can removing them fix the damage? To find out, they treated the sick mice with a compound designed to lower the levels of these specific molecules. The result was dramatic. The treated mice survived, their blood sugar stabilized, their liver damage stopped, and their cells regained the ability to breathe and burn fuel efficiently. In contrast, when the researchers tried to fix the problem by giving the mice the chemical that the enzyme usually produces, it did not help. In fact, that approach made the levels of the toxic fat carriers even higher.

This work suggests that the trouble caused by blocking this enzyme is not just about a lack of a specific building block, but rather about a traffic jam of fat molecules that the cell cannot clear. The study indicates that the symptoms seen in patients and the severe illness in the mice share a common root: the failure to process long-chain fats, leading to a toxic accumulation that disrupts cellular function. By showing that clearing this backlog can restore health in the animal model, the research points toward a new way to think about treating these side effects. Instead of just trying to work around the enzyme block, the findings suggest that helping the body manage the resulting buildup of fat carriers could be a viable path to preventing the muscle pain and other metabolic disturbances that sometimes accompany cholesterol treatment. The study confirms that this specific metabolic signature is a real consequence of the treatment and offers a concrete target for future therapies.